|
|||||
|
|
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2? |
|
| Authors: | Kristine M Frizzell W Lee Kraus |
| Affiliation: | 1. Department of Molecular Biology and Genetics, Cornell University, 465 Biotechnology Building, Ithaca, NY, 14853, USA 2. Graduate Field of Biochemistry, Molecular and Cell Biology, Cornell University, 465 Biotechnology Building, 14853, Ithaca, NY, USA 3. Department of Pharmacology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY, 10021, USA |
| Abstract: | Poly(ADP-ribose) polymerase (PARP) inhibitors have been explored as therapeutic agents for the treatment of hereditary breast and ovarian cancers harboring mutations in BRCA1 or BRCA2. In a new study, Inbar-Rozensal and colleagues show that phenanthridine-derived PARP inhibitors promote cell cycle arrest and cell death in breast cancer cells lacking BRCA1 and BRCA2 mutations and prevent the growth of tumors from xenografts of these cells in immunocompromised mice. These results suggest a potential broader utility of PARP-1 inhibitors in the treatment of breast cancer, although further mechanistic studies are needed. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |